A further bispecific, humanized IgG1 antibody that is less than investigation is zenocutuzumab (MCLA-128), which functions by means of two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by means of ADCC. MCLA-128 capabilities by way of a ‘dock and block’ system whereby one arm with the ant